In April, BioMarin forecast that its new gene therapy Roctavian would bring in $50 million to $100 million in sales by the end of 2023. Instead, it’s collected just $3.5 million in revenue for a mere three patients.
While the company had significantly lowered expectations late last year, and Wall Street had lowered them further, the paltry sales are yet another reminder of just how challenging it can be to deliver complex, high-cost new gene therapies to the market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.